Rolf F Barth

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas
    Rolf F Barth
    The Ohio State University, Department of Pathology, 4132 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA Electronic address
    Appl Radiat Isot 88:38-42. 2014
  2. pmc Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats
    Tianyao Huo
    Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e48752. 2012
  3. doi request reprint Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors
    Weilian Yang
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Radiat Oncol 9:25. 2014
  4. pmc Intracerebral delivery of carboplatin in combination with either 6 MV photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma
    Laure Bobyk
    INSERM U836 Équipe 6, Grenoble Institut des Neurosciences, Grenoble, France
    J Exp Clin Cancer Res 31:78. 2012
  5. doi request reprint Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Appl Radiat Isot 69:1813-6. 2011
  6. pmc Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH, 43210, USA
    Radiat Oncol 7:146. 2012
  7. pmc Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
    J Neurooncol 94:299-312. 2009
  8. doi request reprint Boron neutron capture therapy at the crossroads: challenges and opportunities
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    Appl Radiat Isot 67:S3-6. 2009
  9. pmc Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors
    Rolf F Barth
    Department of Pathology, Division of Biostatistics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:17493-7. 2008
  10. pmc Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors
    Weilian Yang
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
    J Neurooncol 95:355-65. 2009

Collaborators

Detail Information

Publications48

  1. ncbi request reprint Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas
    Rolf F Barth
    The Ohio State University, Department of Pathology, 4132 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA Electronic address
    Appl Radiat Isot 88:38-42. 2014
    ..Our data suggest that further studies are warranted to evaluate these compounds prior to the initiation of clinical studies. ..
  2. pmc Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats
    Tianyao Huo
    Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e48752. 2012
    ..c. by CED for the treatment of brain tumors and that a formulation that may be safe when given systemically may be highly neurotoxic when administered directly into the brain...
  3. doi request reprint Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors
    Weilian Yang
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Radiat Oncol 9:25. 2014
    ..c.) administration of carboplatin to F98 glioma bearing rats could improve survival over that previously reported by us with a 15 Gy dose (5 Gy × 3) of 6 MV photons...
  4. pmc Intracerebral delivery of carboplatin in combination with either 6 MV photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma
    Laure Bobyk
    INSERM U836 Équipe 6, Grenoble Institut des Neurosciences, Grenoble, France
    J Exp Clin Cancer Res 31:78. 2012
    ....
  5. doi request reprint Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Appl Radiat Isot 69:1813-6. 2011
    ..However, a significant problem that must be solved for both BNCT and this new chemoradiotherapeutic approach is how to improve drug uptake and microdistribution within the tumor...
  6. pmc Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH, 43210, USA
    Radiat Oncol 7:146. 2012
    ..Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options...
  7. pmc Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
    J Neurooncol 94:299-312. 2009
    ..It is essential to recognize the limitations of each of the models that have been described, and depending upon the nature of the study to be conducted, it is important that the appropriate model be selected...
  8. doi request reprint Boron neutron capture therapy at the crossroads: challenges and opportunities
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    Appl Radiat Isot 67:S3-6. 2009
    ..These challenges notwithstanding, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy...
  9. pmc Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors
    Rolf F Barth
    Department of Pathology, Division of Biostatistics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:17493-7. 2008
    ..Further studies are planned to design and synthesize 3CTAs with enhanced chemical and biological properties, and increased therapeutic efficacy...
  10. pmc Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors
    Weilian Yang
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
    J Neurooncol 95:355-65. 2009
    ..006), following i.c CED of BD-EGF compared to i.t injection, and that the survival data were equivalent to those previously reported by us using the boronated anti-human-EGF mAb, C225 (cetuximab)...
  11. ncbi request reprint Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas
    Weilian Yang
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    Appl Radiat Isot 61:981-5. 2004
    ..These data show that CED improved the radiobiological effectiveness of BD-EGF and lay the groundwork for future studies using combinations of boron delivery agents for NCT of EGFR(+) gliomas...
  12. ncbi request reprint Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4
    Weilian Yang
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, 43210, USA
    Clin Cancer Res 12:3792-802. 2006
    ..The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-positive rat glioma, F98(npEGFRvIII)...
  13. ncbi request reprint Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent
    Rolf F Barth
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    Appl Radiat Isot 61:899-903. 2004
    ..These data are the first to demonstrate the efficacy of a boronated MoAb for BNCT of an intracerebral (i.c.) glioma and are paradigmatic for future studies using a combination of boronated MoAbs and low molecular weight delivery agents...
  14. ncbi request reprint Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors
    Rolf F Barth
    Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Int J Radiat Oncol Biol Phys 58:267-77. 2004
    ..Two brain tumor models were used, the F98 glioma as a model for primary brain tumors and the MRA 27 human melanoma as a model for metastatic brain tumors...
  15. ncbi request reprint Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy
    Youngjoo Byun
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    J Med Chem 48:1188-98. 2005
    ..2004, 64, 6280-6286 and 6287-6295). To complete previous structure-activity relationship (SAR) studies, 3-[(closo-o-carboranyl)methyl]thymidine (4) was also synthesized and evaluated...
  16. ncbi request reprint Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab
    Gong Wu
    Department of Pathology, The Ohio State University, Columbus 43210, USA
    Clin Cancer Res 13:1260-8. 2007
    ....
  17. ncbi request reprint Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy
    Gong Wu
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, Ohio 43210, USA
    Anticancer Agents Med Chem 6:167-84. 2006
    ..Finally, we will conclude with a discussion relating to issues that must be addressed if these HMW agents are to be used clinically...
  18. doi request reprint Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors
    Weilian Yang
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    J Neurooncol 101:379-90. 2011
    ....
  19. ncbi request reprint Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 64:6287-95. 2004
    ..Based on these favorable in vitro and in vivo data, neutron capture therapy studies will be initiated using N5-2OH in combination with two non-cell cycle dependent boron delivery agents, boronophenylalanine and sodium borocaptate...
  20. pmc Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy
    Elena Sjuvarsson
    Department of Anatomy, Physiology, and Biochemistry, The Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden E S, S E Department of Oncology, University of Alberta, Edmonton, Alberta, Canada V L D, D M, M B S, C E C Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, Ohio R T, H K A, A K, S H, A G, W T Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt A K Division of Pharmaceutical Organic Chemistry, College of Pharmacy, Helwan University, Ain Helwan, Cairo, Egypt S H Division of Pharmacology, College of Veterinary Medicine, Cairo University, Giza, Egypt A G and Department of Pathology, The Ohio State University, Columbus, Ohio R J N, R F B
    J Pharmacol Exp Ther 347:388-97. 2013
    ..Our results provide valuable information on the cellular metabolism and pharmacokinetic profile of 3-carboranyl thymidine analogs. ..
  21. ncbi request reprint Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors
    Youngjoo Byun
    Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH, USA
    J Med Chem 49:5513-23. 2006
    ....
  22. ncbi request reprint Boronated thymidine analogues for boron neutron capture therapy
    B T S Thirumamagal
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43120, USA
    Nucleosides Nucleotides Nucleic Acids 25:861-6. 2006
    ..The synthesis of these potential boron neutron capture therapy (BNCT) agents and their preliminary biological evaluation is described...
  23. doi request reprint Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies
    Weilian Yang
    Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 14:883-91. 2008
    ....
  24. ncbi request reprint Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4
    Weilian Yang
    Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:341-50. 2005
    ..t., and convection enhanced delivery to brain tumor-bearing rats...
  25. ncbi request reprint Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy
    Stacy M Stephenson
    Division of Pharmaceutics, Ohio State University, Columbus, OH 43210, USA
    Anticancer Res 23:3341-5. 2003
    ..In the present study we have evaluated the delivery of Na3(B20H17NH3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor...
  26. ncbi request reprint Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy
    Gong Wu
    Department of Pathology and College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Bioconjug Chem 15:185-94. 2004
    ..t. injection, thereby demonstrating specific molecular targeting of EGFR. Based on these data, BNCT studies will be initiated in F98EGFR glioma bearing rats to evaluate C225-G5-B1100 for the treatment of intracerebral brain tumors...
  27. ncbi request reprint Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy
    Supriya Shukla
    College of Pharmacy, Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Bioconjug Chem 14:158-67. 2003
    ..0% ID/g tumor), but also high hepatic (38.8% ID/g) and renal (62.8% ID/g) uptake, indicating that attachment of a second PEG unit and/or folic acid may adversely affect the pharmacodynamics of this conjugate...
  28. ncbi request reprint 3-Carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy
    Youngjoo Byun
    College of Pharmacy, The Ohio State University, Columbus, OH, USA
    Anticancer Agents Med Chem 6:127-44. 2006
    ..This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed...
  29. ncbi request reprint Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates
    Gong Wu
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, 43210, USA
    Mol Cancer Ther 5:52-9. 2006
    ..Our results, which are both positive and negative, show that specific molecular targeting is but one of several requirements that must be fulfilled if an antibody-drug bioconjugate will be therapeutically useful...
  30. ncbi request reprint Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas
    Weilian Yang
    Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 62:6552-8. 2002
    ..t. injection and 12.3%ID/g in F98(WT) gliomas. On the basis of these observations, we have concluded that CED is more effective than i.t. injection as a way to deliver boronated EGF to EGFR (+) gliomas for boron neutron capture therapy...
  31. ncbi request reprint Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas
    Rolf F Barth
    Department of Pathology, The Ohio State University, 1645 Neil Avenue, Columbus, OH 43210, USA
    Cancer Res 62:3159-66. 2002
    ....
  32. ncbi request reprint Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy
    Jennifer J Sudimack
    College of Pharmacy, The Ohio State University, Columbus 43210, USA
    Pharm Res 19:1502-8. 2002
    ..This study was aimed at the in vitro evaluations of folate receptor (FR)-targeted liposomes as carriers for a lipophilic boron agent, K[nido-7-CH3(CH2)15-7,8-C2B9H11, in FR-overexpressing tumor cells for neutron capture therapy...
  33. pmc Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR
    Xiaogang Pan
    Division of Pharmaceutics, College of Pharmacy, NSF Nanoscale Science and Engineering Center NSEC, Center for Affordable Nanoengineering of Polymeric Biomedical Devices CANPBD, The Ohio State University, Columbus, Ohio 43210, USA
    Bioconjug Chem 18:101-8. 2007
    ..On the basis of these observations, we have concluded that cholesterol can serve as an effective anchor for MAb in liposomes, and cetuximab-ILs are potentially useful delivery vehicles for BNCT of gliomas...
  34. ncbi request reprint Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy
    Christopher R Gibson
    College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH, USA
    J Neurooncol 62:157-69. 2003
    ..v. infusion. The results from our study are confirmatory of those previously reported by others when blood sampling has been carried out for a sufficient period of time to adequately characterize the pharmacokinetics...
  35. ncbi request reprint Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT)
    B T S Thirumamagal
    Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, 43210, USA
    Bioconjug Chem 17:1141-50. 2006
    ....
  36. ncbi request reprint Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    J Neurooncol 62:61-74. 2003
    ..Be that as it may, rat brain tumor models already have made a significant contribution to the design of clinical BNCT protocols, and should continue to do so in the future...
  37. pmc Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery
    Chenguang Zhou
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Int J Pharm 392:201-8. 2010
    ....
  38. pmc Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues
    Rohit Tiwari
    Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA
    Inorg Chem 51:629-39. 2012
    ..0% to 29.6% relative to that of thymidine, the endogenous hTK1 substrate. The in vitro uptake of N5, N5-(127)I, and N5-(79/81)Br in L929 TK1(+) cells was 2.0, 1.8, and 1.4 times greater than that in L929 TK1(-) cells...
  39. ncbi request reprint Effects of l-DOPA pre-loading on the uptake of boronophenylalanine using the F98 glioma and B16 melanoma models
    Weilian Yang
    The Ohio State University, Department of Pathology, Columbus, OH 43210, USA
    Appl Radiat Isot 88:69-73. 2014
    ..In vivo studies in B16 melanoma bearing mice showed equivalent tumor boron values in treated and untreated mice, suggesting that the effects of l-DOPA pre-loading may depend both on the histologic type of tumor and its anatomic site. ..
  40. ncbi request reprint Boron neutron capture therapy of cancer: current status and future prospects
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:3987-4002. 2005
    ..Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT...
  41. ncbi request reprint Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine
    Rolf F Barth
    Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Int J Radiat Oncol Biol Phys 52:858-68. 2002
    ....
  42. ncbi request reprint Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy
    Xing Q Pan
    College of Pharmacy and Department of Pathology, The Ohio State University, Columbus 43210, USA
    Bioconjug Chem 13:435-42. 2002
    ..Our findings suggest that further evaluation of FR-targeted liposomes is warranted to assess their potential as boron carriers for neutron capture therapy...
  43. pmc Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist
    Frederick K Racke
    Department of Pathology, The Ohio State University School of Medicine, Columbus, Ohio, United States of America
    PLoS ONE 7:e51059. 2012
    ..Our data demonstrate that novel PKC isoform agonists such as IDB may represent a unique therapeutic strategy for accelerating the recovery of platelet counts following severe marrow injury...
  44. pmc High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide
    Gregory A Christoforidis
    Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Invest Radiol 44:375-83. 2009
    ..In an effort to explain differences in visualization of microvascularity before and after USPIO administration, hypoxia and vessel diameters were assessed on corresponding histopathologic sections...
  45. ncbi request reprint Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, Medical Genetics, The Ohio State University, Columbus, Ohio, 43210, USA
    Cancer Res 63:965-71. 2003
    ..These results suggest that antiviral therapies can be effectively explored in vivo using a preclinical animal model of human EBV(+) PCNSL with subsequent translation to patients with EBV(+) PCNSL...
  46. ncbi request reprint Electrospray ionization mass spectrometry coupled to reversed-phase ion-pair high-performance liquid chromatography for quantitation of sodium borocaptate and application to pharmacokinetic analysis
    Christopher R Gibson
    College of Pharmacy, Department of Pathology, The Ohio State University, Columbus 43210, USA
    Anal Chem 74:2394-9. 2002
    ..The mean total body plasma clearance was 95.7 +/- 30.8 m/min and the harmonic mean terminal half-life was 3.6 h...
  47. ncbi request reprint Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation?
    Rolf F Barth
    Department of Pathology, The Ohio State University, OH, USA
    Radiother Oncol 82:119-22. 2007
  48. ncbi request reprint A critical assessment of boron neutron capture therapy: an overview
    Rolf F Barth
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    J Neurooncol 62:1-5. 2003
    ..Clinical studies have demonstrated the safety of BNCT. The next challenge is an unequivocal demonstration of therapeutic efficacy in one or more of the clinical trails that either are in progress or are planned over the next few years...